<DOC>
	<DOCNO>NCT01972074</DOCNO>
	<brief_summary>This study 12-week randomized-controlled trial memantine hydrochloride ( Namenda ) treatment social impairment adolescent autism spectrum disorder ( ASD ) . The investigator also conduct pre- post-treatment neuroimaging ( fMRI HMRS ) assess neural functional deficit adolescent ASD compare healthy volunteer adolescent assess effect memantine therapy neural function adolescent ASD . The investigator hypothesize short-term memantine monotherapy safe , well-tolerated , effective improve core symptom autism spectrum disorder adolescent ASD . Additionally , investigator hypothesize follow memantine therapy , ASD subject exhibit decrease glutamate ( Glu ) concentration anterior-cingulate cortex ( ACC ) change towards normalization alter functional connectivity ACC medial temporal lobe , consistent improvement social impairment ASD . The investigator hypothesize compare healthy volunteer subject , ASD subject significantly differ neuroimaging measure baseline follow memantine therapy , difference ASD healthy volunteer neuroimaging data decrease .</brief_summary>
	<brief_title>Behavioral Neural Response Memantine Adolescents With Autism Spectrum Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Inclusion Criteria ( participant ) 1 . Male &amp; female subject age 817 year ( inclusive ) . Participants ASD 3 . DSM5 ASD diagnostic criterion establish clinical diagnostic interview 4 . At least moderate severity social impairment measure total raw score ≥85 parent/guardiancompleted Social Responsiveness ScaleSecond Edition ( SRS2 ) score ≥4 clinicianadministered Clinical Global ImpressionSeverity scale ( CGIS ) . Healthy Control Participants 3 . Age , sex , &amp; IQmatched . 4 . No Axis I diagnose establish Kiddie Schedule Affective Disorders Schizophrenia—Epidemiological Version ( KSADSE ) &amp; confirm clinical diagnostic interview . 5 . No significant trait ASD screen SRS2 ( raw score &lt; 60 ) . Exclusion Criteria ( participant ) 1 . IQ ≤70 base Wechsler Abbreviated Scale IntelligenceII ( WASIII ) Vocabulary Matrix Reasoning subtests 2 . Impaired communicative speech 3 . Subjects currently treat follow medication ( know impact glutamate level ) : 1 . Lamotrigine 2 . Amantadine 3 . Nacetylcysteine 4 . Dcycloserine 4 . Subjects treat psychotropic medication list dose stable least 4 week prior study baseline . 5 . Coadministration drug compete memantine renal elimination use renal cationic system , include hydrochlorothiazide , triamterene , metformin , cimetidine , ranitidine , quinidine , nicotine 6 . Initiation new psychosocial intervention within 30 day prior randomization . 7 . Contraindications MR scanning ( claustrophobia , brace , metal body , etc . ) 8 . Subjects pregnant and/or nursing . 9 . Subjects history nonfebrile seizure without clear resolve etiology . 10 . Subjects history current liver kidney disease . 11 . Clinically unstable psychiatric condition judge serious suicidal risk . 12 . History substance use ( except caffeine ) within past 3 month 13 . Serious , stable unstable systemic illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . 14 . Subjects severe hepatic impairment ( LFTs &gt; 3 time ULN ) . 15 . Subjects genitourinary condition raise urine pH ( e.g. , renal tubular acidosis , severe infection urinary tract ) . 16 . Known hypersensitivity memantine . 17 . Severe allergy multiple adverse drug reaction . 18 . A nonresponder history intolerance memantine , treatment adequate dos determine clinician . 19 . Investigator his/her immediate family define investigator 's spouse , parent , child , grandparent , grandchild .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Autism spectrum disorder</keyword>
	<keyword>Treatment</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Memantine</keyword>
	<keyword>functional Magnetic Resonance Imaging</keyword>
	<keyword>MRS</keyword>
	<keyword>Neuroimaging</keyword>
</DOC>